Novo Nordisk ® d to activate more people with and improve market access ~2.5 million seen by obesity experts 2.5 Treated ~1 million with Saxenda ® in 2021 1 Only 25% on treatment for more than 1 year 0.25 Maximize the value of Novo Nordisk’s superior treatment solutions Marketed product portfolio and pipeline closing the treatment gaps Approved products Late-stage pipeline products Oral semaglutide 50 mg CagriSema
Download PDF file